MicroRNA-29 family, a crucial therapeutic target for fibrosis diseases

被引：262

作者：

He, Yong ^{[1
,2
]}

Huang, Cheng ^{[1
,2
]}

Lin, Xiang ^{[1
,2
]}

Li, Jun ^{[1
,2
]}

机构：

[1] Anhui Med Univ, Sch Pharm, Anhui Key Lab Bioact Nat Prod, Hefei 230032, Anhui, Peoples R China

[2] Anhui Med Univ, Inst Liver Dis, Hefei 230032, Anhui, Peoples R China

来源：

BIOCHIMIE | 2013年 / 95卷 / 07期

基金：

美国国家科学基金会;

关键词：

miR-29; family; Extracellular matrix; Fibrosis diseases; Review; HEPATIC STELLATE CELLS; IDIOPATHIC PULMONARY-FIBROSIS; FARNESOID-X RECEPTOR; LIVER FIBROSIS; RENAL FIBROSIS; TGF-BETA; DNA METHYLTRANSFERASES; CELLULAR MECHANISMS; CARDIAC FIBROSIS; TISSUE FIBROSIS;

D O I：

10.1016/j.biochi.2013.03.010

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

070307 [化学生物学]; 071010 [生物化学与分子生物学];

摘要：

MicroRNAs (miRNAs) are a class of approximately 20-nucleotides single-stranded endogenous RNAs that regulate gene expression at the post-transcriptional level. miRNAs have recently been known to regulate cell proliferation, differentiation, and apoptosis. Fibrosis is the leading cause of organ dysfunction in diseases and results from an imbalance in the turnover of extracellular matrix components. Accumulating studies have demonstrated that miR-29 family participates in the development of liver fibrosis, renal fibrosis, pulmonary fibrosis, cardiac fibrosis. In this review, we are discussing the comprehensive role of miR-29 family in moderating profibrotic effect and its potential as therapeutic approach to fibrosis diseases. (C) 2013 Elsevier Masson SAS. All rights reserved.

引用

页码：1355 / 1359

页数：5

共 66 条

[1]

A new target for renal fibrosis? [J].